Manifold
76 employees on LinkedIn · 5 known investors
Find your way into Manifold
645 people in our graph share verified history with the Manifold team — schools, employers, funds. One of them is your warm intro.
Yaryna Nychunlockedknows Pierce Ogden · together at Harvard University (overlapped)
×5knows the team · via Harvard University
×4knows the team · via Harvard Medical School
×2knows the team · via University of San Francisco
Manifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.
Founders & leadership
GK
Gleb KuznetsovinCo-Founder & CEO
PO
Pierce OgdeninCo-Founder & CTOPierce Ogden is co-founder and CTO of Manifold Bio, which develops AI-guided protein design and high-throughput screening methods for engineering tissue-targeted biologics. Previously, he conducted research in the Church lab on AAV variant screening using DNA synthesis and sequencing methods, work that contributed to the founding of Dyno Therapeutics.
Investors · 5
Competitors · 4
by search overlap
Form Bio26 shared keywordsForm Bio develops AI-driven software and bioinformatics tools for genetic medicine and genome engineering, enabling faster and safer design of gene therapies, protein engineering, and manufacturing optimization.
Mammoth Biosciences26 shared keywordsMammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
Talus Bio24 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Bridgebio22 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Companies competing with Manifold for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Manifold do?
- Manifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.
- Who founded Manifold?
- Manifold was founded by Gleb Kuznetsov, Pierce Ogden.
- Who are Manifold's investors?
- Manifold's investors include Playground Global, Fifty Years, FPV, Horizons Ventures, Triatomic Capital.